Cancer Genetics Inc. (CGIX)

1.80
NASDAQ : Health Services
Prev Close 1.77
Day Low/High 1.75 / 1.85
52 Wk Low/High 1.55 / 5.30
Avg Volume 235.70K
Exchange NASDAQ
Shares Outstanding 27.70M
Market Cap 48.48M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cancer Genetics To Participate In Upcoming Investor Conferences

Cancer Genetics To Participate In Upcoming Investor Conferences

LD Micro Main Event and Benchmark Micro Cap Conference

Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann To Its Board Of Directors

Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann To Its Board Of Directors

Founder of Multiple Successful Biotech Companies Including Actelion Pharmaceuticals, Sold to Johnson & Johnson for $30 Billion

Cancer Genetics Reports Record Third Quarter 2017 Revenue And 134% Increase In Contracted Bookings From Major Biotech And Pharmaceutical Companies

Cancer Genetics Reports Record Third Quarter 2017 Revenue And 134% Increase In Contracted Bookings From Major Biotech And Pharmaceutical Companies

Company Also Increased Number of Clinical Trials and Studies it Supports to 191, up 59%

Cancer Genetics, Inc. To Host Conference Call To Discuss Strategic And Business Rationale Of vivoPharm Acquisition

Cancer Genetics, Inc. To Host Conference Call To Discuss Strategic And Business Rationale Of vivoPharm Acquisition

Conference call scheduled for Tuesday, August 22, 2017- 8:30 AM Eastern

TheStreet Quant Rating: D- (Sell)